
Serotype 3 IPD Persists in Older Adults Despite PCV Vaccination
Key Takeaways
- Serotype 3 persists as a leading cause of older-adult IPD despite PCV implementation, reflecting limited indirect protection and continued disease burden across multiple high-income regions.
- Immune evasion is facilitated by capsule shedding from noncovalent capsule attachment, neutralizing antibodies and reducing effective opsonophagocytic killing relative to other serotypes.
Pharmacists who vaccinate older adults face a serotype that current conjugate vaccines have yet to control.
Serotype 3 caused 14.7% to 18.9% of invasive pneumococcal disease (IPD) cases among adults 65 and older in Europe, the US, and Australia from 2018 to 2023, according to a study published in Vaccine: X.1
“It’s good news that more pneumococcal serotypes are now targeted with pneumococcal conjugate vaccines (PCVs),” said John D. Grabenstein, PhD, RPh, former director of scientific communication for Immunize.org, according to a release from the American Pharmacists Association.2 “Of greatest importance is reaching the millions of adults who have never received the protection of pneumococcal vaccines or are not up to date on their adult vaccines.”
However, despite the large-scale implementation of PCVs across the various locales explored in the current study, serotype 3 continues to challenge even the populations most led to vaccinate. In turn, these developments have led researchers to explore the population-wide burden of IPD among adults at least 65 years old, while also assessing the potential of Multiple Antigen Presenting System (MAPS) technology for improving immunization.
READ MORE:
Molecular Mechanisms Driving Vaccine Evasion and Clonal Shifts
The persistent burden of serotype 3 in older adults is largely driven by unique biological attributes that allow the pathogen to escape vaccine-induced immunity. Unlike other pneumococcal serotypes, serotype 3 non-covalently attaches its polysaccharide capsule to the cell wall, shedding large amounts of capsular material that neutralizes circulating antibodies before they can trigger bacterial killing.1,3
Molecular surveillance over 30 years in Spain demonstrates that serotype 3 incidence in adults remained remarkably stable despite high childhood vaccination rates with the 13-valent conjugate vaccine (PCV13), demonstrating a lack of indirect herd immunity. Over this period, genomic analysis revealed a major clonal shift in which the PCV13-susceptible clonal complex 260 was gradually replaced with the dominant clonal complex 180.3,4
Further experimental research published in Lancet Microbe identified a hypervirulent clade within clonal complex 180, designated clade I-alpha, which carries a key single amino acid substitution in the autolysin protein LytA. This specific mutation increases LytA enzymatic activity, enhancing the bacterium's capacity to divert C3 complement deposition, resist phagocytosis, and adhere to human lung cells.4
Patients infected with this lineage exhibited a high prevalence of severe cardiac and respiratory comorbidities, underscoring the clinical severity of emerging variants.
Furthermore, longitudinal clinical data indicate that adult patients hospitalized with serotype 3 experience high rates of underlying medical conditions, such as diabetes, and face persistent 30-day mortality rates near 24%.3
Public Health Gaps and Emerging Vaccine Recommendations
Beyond bacterial evolution, low immunization coverage among vulnerable adults presents a significant public health barrier. According to a CDC survey, fewer than 40% of eligible US adults had received a pneumococcal vaccine by early 2024, leaving the rest of the population unprotected. Unvaccinated adults frequently cited a lack of familiarity with vaccine guidance or noted that their health care provider had never recommended immunization.1,5
To overcome implementation barriers associated with complex risk-based criteria, the Advisory Committee on Immunization Practices (ACIP) updated its guidelines to recommend routine, age-based pneumococcal vaccination for all adults 50 and older.5
For pharmacists managing adult immunization schedules, current ACIP guidelines specify administering either PCV20 alone or PCV15 followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23).2
Expanding age-based recommendations enables pharmacists to identify and vaccinate high-risk adults earlier, addressing critical gaps in community protection. As clinicians trusted by 63% of survey respondents, pharmacists are uniquely positioned to assess vaccination status during routine consultations and educate patients on preventable respiratory risks.2,5
Next Generation MAPS Technology Offers Future Hope
Because existing PCVs struggle to induce sufficient antibody thresholds against serotype 3, researchers are evaluating innovative platform technologies to improve clinical outcomes. MAPS technology combines capsular polysaccharides with conserved pneumococcal carrier proteins, inducing a multifaceted immune response that targets both the outer capsule and essential bacterial proteins.1,3
In preclinical sepsis models, passive immunization with MAPS-induced antibodies provided significantly greater protection against lethal serotype 3 infection compared with PCV13-induced antibodies.1
Clinical evaluations of an investigational 24-valent MAPS vaccine (Pn-MAPS24v) have demonstrated encouraging results in adults aged 65 to 85. Trial data showed that Pn-MAPS24v elicited significantly higher functional opsonophagocytic antibody titers against serotype 3 compared with standard conjugate and polysaccharide vaccines.
By inducing broader immune responses, next-generation technologies such as MAPS offer pharmacists and health care systems a promising strategy to finally control serotype 3 IPD in aging populations.1
“[Although] public health policies centered on the use and development of current PCVs have led to a reduction in the overall prevalence of S. pneumoniae IPD, epidemiological data consistently demonstrate that serotype 3 remains a significant cause of IPD in older adults in Europe, the US, and Australia,” concluded authors of the current study.1 “Novel preventive strategies, such as MAPS technology-based pneumococcal vaccines, highlight a promising avenue to address the challenge of serotype 3 more effectively than currently licensed PCVs, thereby potentially improving clinical outcomes and enhancing public health strategies, once demonstrated and licensed.”
READ MORE:
REFERENCES
1. Volpe S, Aris E, Stevenson TC, et al. Understanding the burden of invasive pneumococcal disease attributable to serotype 3 in older adults in Europe, the United States, and Australia, and the potential of MAPS technology-based pneumococcal vaccines. Vaccine: X. 2026;33:100929. doi:10.1016/j.jvacx.2026.100929
2. Sartain M. ACIP updates adult recommendations for pneumococcal vaccines. American Pharmacists Association. May 9, 2022. Accessed November 19, 2026. https://www.pharmacist.com/Publications/Transitions/acip-updates-adult-recommendations-for-pneumococcal-vaccines
3. Calvo-Silveria S, González-Díaz A, Grau I, et al. Evolution of invasive pneumococcal disease by serotype 3 in adults: a Spanish three-decade retrospective study. Lancet Reg Health Eur. 2024;41:100913. 2024 May 3. doi:10.1016/j.lanepe.2024.100913
4. Pérez-García C, Sempere J, Llamosí M, et al. Upsurge of pneumococcal clade I-α/CC180 serotype 3 and its association with a LytA mutation linked to immune evasion and disease potential: an observational and experimental study. Lancet Microbe. 2026;7(7):101365. doi:10.1016/j.lanmic.2026.101365
5. Beusekom MV. 6 in 10 US adults eligible for pneumococcal vaccine don't receive it, survey suggests. University of Minnesota. September 17, 2025. Accessed November 19, 2026. https://www.cidrap.umn.edu/pneumonia/6-10-us-adults-eligible-pneumococcal-vaccine-dont-receive-it-survey-suggests
Related to this article








